Results From Positive Phase 1 Study of NovaDigm Therapeutics ’ NDV-3 Vaccine for Candida and Staph Infections Published in Vaccine

Published: Dec 13, 2012

GRAND FORKS, N.D.--(BUSINESS WIRE)--NovaDigm Therapeutics, a company developing innovative vaccines for fungal and bacterial infections, today announced the publication of data from its first-in-human Phase 1 study of its NDV-3 vaccine program in the journal Vaccine. The data demonstrate that a single dose of NDV-3 with alum adjuvant was safe, well-tolerated and induced strong antibody and T-cell immune responses in healthy adults.

Back to news